After working at a paper manufacturing company and Oracle, the pull of working as an entrepreneur proved to string for Nitin Khanna to ignore. Nitin Khanna joined his brother in the establishment of Saber Software in Portland, Oregon in 1999 as the chaos of the 2000 Presidential elections between President George W. Bush and Vice-president Al Gore. The battle in Florida over the legality of the Presidential vote gave the Khanna brothers their entry into the big leagues of the software industry.
Basing Saber Software in Portland, Oregon proved a fortuitous move for Nitin Khanna as the state was the first to act upon a congressional requirement to update the voting software used in state elections. The state of Oregon awarded the contract to Saber Software and helped launch the career of Nitin Khanna as an entrepreneur who was destined for the top of various industries. By 2008, Saber Software was providing its skills in updating the election software used in all elections to 21 states in the U.S. and was having a global impact on this industrial sector. Nitin Khanna would eventually employ more than 1,500 people at Saber Software producing annual revenues of $300 million. The sale of Saber to EDS for $1,200 million led to Khanna becoming one of the leading figures in the mergers and acquisitions sector of the U.S. economy.
Cancer research has been an area of interest in many companies including Seattle Genetics. Clay Siegall co-founded Seattle Genetics in 1998 and has been the CEO and President since the year 2002. Dr. Siegall has worked hard to lead the company to reach great heights; they have come up with cancer therapies that are so helpful to cancer patients and also made huge advancement in cancer research. Seattle Genetics main aim is intense research, drug development, scientific innovation and helping patients.
Clay Siegall is keen in implementing improve cancer research developments; under his leadership, Seattle Genetics introduced the first antibody-drug conjugates for helping cancer patients. FDA approved the drug in 2011, current it is available to patients in over sixty countries. Dr. Siegall’s determination and persistence prompt the approval; he is not planning to stop as he wants to make sure cancer therapies are made a priority.
To enable Seattle Genetics to continue innovation with high-tech technology, Clay facilitated a fundraising that raised more than $1.2 billion from both private and public funding. He continues to find ways to help cancer patients and currently holds fifteen patents.
Clay Siegall has a Ph.D. in Genetics acquired at the George Washington University and a Bachelor of Science in Zoology from the University of Maryland. Before co-founding Seattle Genetics, Clay worked at Bristol-Myers Squibb Pharmaceutical as a Senior Research Investigator and later rose to Principal Scientist. He then moved to the National Cancer Institute as Staff and Biotechnology Fellow. Working for these organizations earned him valuable experience that Clay uses to date.
The University of Maryland awarded Clay Siegall with the alumnus of the year for computer, math and natural science in 2013. In 2012 he was awarded the Pacific Northwest Ernst & Young Entrepreneur of the Year. He has a potion in editorial team of three different scientific journals; this is used as a platform for researchers and medics to share information and discoveries. Dr. Siegall has written over seventy journals they are a good source of information in the medical and scientific field. His passion for helping the sick gives hope mainly because cancer patients know he is working hard to bring better innovations that will help them.